Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization

The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2007
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/27007
Acceso en línea:
https://doi.org/10.1016/j.vaccine.2007.03.016
https://repository.urosario.edu.co/handle/10336/27007
Palabra clave:
SPf66
Malaria
MALDI-TOF
DC
HPLC
NMR
Immunogenicity
Rights
License
Restringido (Acceso a grupos específicos)
id EDOCUR2_779a42598da994023c720c8c7d494f8c
oai_identifier_str oai:repository.urosario.edu.co:10336/27007
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 51890881600796530656006fc431a4-2889-4e78-ba01-10c2807c6557-11450e86b-c3ae-413a-bffa-4caa6fae204a-151721018-12b450674-ab40-46a4-8e3b-a2e6b0ca0d5d-16ba07db9-25c9-4c23-92eb-ee6f82cfbd87-15bda2be9-f7a2-4a95-a75d-15354ebec39d-19e3ba9df-fe89-48fe-9521-cc8f452d56f5-12020-08-19T14:40:44Z2020-08-19T14:40:44Z2007-05-30The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches.application/pdfhttps://doi.org/10.1016/j.vaccine.2007.03.016ISSN: 0264-410XEISSN: 1873-2518https://repository.urosario.edu.co/handle/10336/27007engThe Japanese Society for VaccinologyElsevier4501No. 224487VaccineVol. 25Vaccine, ISSN: 0264-410X;EISSN: 1873-2518, Vol.25 , No.22 (2007); pp. 4487-4501 https://www.sciencedirect.com/science/article/pii/S0264410X07003106?via%3DihubRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecVaccineinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURSPf66MalariaMALDI-TOFDCHPLCNMRImmunogenicitySynthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterizationActualización de la vacuna sintética: aplicación de las lecciones aprendidas de la reciente caracterización fisicoquímica, estructural e inmunológica de la vacuna contra la malaria SPf66articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Bermudez, AdrianaPatarroyo, Manuel A.Reyes, ClaudiaGuzmán, FannyVanegas, MagnoliaRosas, JaiverAmador, RobertoRodríguez, RaulPatarroyo, Manuel Elkin10336/27007oai:repository.urosario.edu.co:10336/270072021-06-03 00:50:04.054https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
dc.title.TranslatedTitle.spa.fl_str_mv Actualización de la vacuna sintética: aplicación de las lecciones aprendidas de la reciente caracterización fisicoquímica, estructural e inmunológica de la vacuna contra la malaria SPf66
title Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
spellingShingle Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
SPf66
Malaria
MALDI-TOF
DC
HPLC
NMR
Immunogenicity
title_short Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
title_full Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
title_fullStr Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
title_full_unstemmed Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
title_sort Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
dc.subject.keyword.spa.fl_str_mv SPf66
Malaria
MALDI-TOF
DC
HPLC
NMR
Immunogenicity
topic SPf66
Malaria
MALDI-TOF
DC
HPLC
NMR
Immunogenicity
description The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches.
publishDate 2007
dc.date.created.spa.fl_str_mv 2007-05-30
dc.date.accessioned.none.fl_str_mv 2020-08-19T14:40:44Z
dc.date.available.none.fl_str_mv 2020-08-19T14:40:44Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.vaccine.2007.03.016
dc.identifier.issn.none.fl_str_mv ISSN: 0264-410X
EISSN: 1873-2518
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/27007
url https://doi.org/10.1016/j.vaccine.2007.03.016
https://repository.urosario.edu.co/handle/10336/27007
identifier_str_mv ISSN: 0264-410X
EISSN: 1873-2518
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 4501
dc.relation.citationIssue.none.fl_str_mv No. 22
dc.relation.citationStartPage.none.fl_str_mv 4487
dc.relation.citationTitle.none.fl_str_mv Vaccine
dc.relation.citationVolume.none.fl_str_mv Vol. 25
dc.relation.ispartof.spa.fl_str_mv Vaccine, ISSN: 0264-410X;EISSN: 1873-2518, Vol.25 , No.22 (2007); pp. 4487-4501
dc.relation.uri.spa.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0264410X07003106?via%3Dihub
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv Restringido (Acceso a grupos específicos)
rights_invalid_str_mv Restringido (Acceso a grupos específicos)
http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv The Japanese Society for Vaccinology
Elsevier
dc.source.spa.fl_str_mv Vaccine
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167567539896320

Publicaciones similares